Data showed overall vaccine efficacy against RSV-lower respiratory tract disease in adults aged 60 years and above| www.gsk.com
Multi-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes| www.gsk.com
DREAMM-3 did not meet its primary endpoint of progression-free survival (PFS)| www.gsk.com